Mechanism of regulation of autoimmunity by iNKT cells

Cytokine

Volumn 53, Issue 3, 2011, Pages 263-270

  Novak, Jan ^a,b   Lehuen, Agnes ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Hôpital Cochin St Vincent de Paul ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autoimmunity; Cell contacts; Cytokines; INKT cells; Regulation

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BULLOUS SKIN DISEASE; CELL MANIPULATION; COLITIS; CYTOKINE PRODUCTION; DERMATOMYOSITIS; EXPERIMENTAL MODEL; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

ANIMALS; ANTIGENS, CD1D; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; NATURAL KILLER T-CELLS;

ANIMALIA;

EID: 79251645844     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.11.001     Document Type: Review

References (130)

1. Bendelac A., Lantz O., Quimby M.E., Yewdell J.W., Bennink J.R., Brutkiewicz R.R. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995, 268:863-865.
2. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev Immunol 2007, 25:297-336.
3. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817-890.
4. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237.
5. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat Immunol 2010, 11:197-206.
6. Kronenberg M., Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002, 2:557-568.
7. Matsuda J.L., Mallevaey T., Scott-Browne J., Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 2008, 20:358-368.
8. Jahng A., Maricic I., Aguilera C., Cardell S., Halder R.C., Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004, 199:947-957.
9. Park S.H., Weiss A., Benlagha K., Kyin T., Teyton L., Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001, 193:893-904.
10. Duarte N., Stenstrom M., Campino S., Bergman M.L., Lundholm M., Holmberg D., et al. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 2004, 173:3112-3118.
11. Berzofsky J.A., Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008, 180:3627-3635.
12. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005, 202:1627-1633.
13. Arase H., Arase N., Nakagawa K., Good R.A., Onoe K. NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol 1993, 23:307-310.
14. Yoshimoto T., Paul W.E. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994, 179:1285-1295.
15. Zlotnik A., Godfrey D.I., Fischer M., Suda T. Cytokine production by mature and immature CD4-CD8- T cells. Alpha beta-T cell receptor+ CD4-CD8- T cells produce IL-4. J Immunol 1992, 149:1211-1215.
16. Hammond K.J., Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity?. Curr Opin Immunol 2003, 15:683-689.
17. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Delovitch T.L. Regulation of autoimmune disease by natural killer T cells. J Mol Med 2002, 80:290-300.
18. Bach J.F., Francois Bach J. Regulatory T cells under scrutiny. Nat Rev Immunol 2003, 3:189-198.
19. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
20. Sireci G., Russo D., Dieli F., Porcelli S.A., Taniguchi M., La Manna M.P., et al. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 2007, 37:425-433.
21. Naumov Y.N., Bahjat K.S., Gausling R., Abraham R., Exley M.A., Koezuka Y., et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001, 98:13838-13843.
22. Shi F.D., Flodstrom M., Balasa B., Kim S.H., Van Gunst K., Strominger J.L., et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001, 98:6777-6782.
23. Wang B., Geng Y.B., Wang C.R. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001, 194:313-320.
24. Yang J.Q., Singh A.K., Wilson M.T., Satoh M., Stanic A.K., Park J.J., et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003, 171:2142-2153.
25. Yang J.Q., Chun T., Liu H., Hong S., Bui H., Van K.L., et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004, 34:1723-1732.
26. Baxter A.G., Kinder S.J., Hammond K.J., Scollay R., Godfrey D.I. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997, 46:572-582.
27. Lehuen A., Lantz O., Beaudoin L., Laloux V., Carnaud C., Bendelac A., et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998, 188:1831-1839.
28. Mars L.T., Laloux V., Goude K., Desbois S., Saoudi A., Van Kaer L., et al. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 2002, 168:6007-6011.
29. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
30. Natori T., Morita M., Akimoto K., Koezuka Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from marine sponge Agelas mauritianus. Tetrahedron 1994, 50:2771-2784.
31. Benlagha K., Weiss A., Beavis A., Teyton L., Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000, 191:1895-1903.
32. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000, 192:741-754.
33. Van Kaer L. Alpha-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005, 5:31-42.
34. Mars L.T., Novak J., Liblau R.S., Lehuen A. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol 2004, 25:471-476.
35. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001, 413:531-534.
36. Schmieg J., Yang G., Franck R.W., Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003, 198:1631-1641.
37. Yu K.O., Im J.S., Molano A., Dutronc Y., Illarionov P.A., Forestier C., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of {alpha}-galactosylceramides. Proc Natl Acad Sci USA 2005, 102:3383-3388.
38. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
39. Bach J.F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994, 15:516-542.
40. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996, 85:291-297.
41. Adorini L., Gregori S., Harrison L.C. Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 2002, 8:31-38.
42. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 1999, 5:601-604.
43. Gombert J.M., Herbelin A., Tancrede-Bohin E., Dy M., Carnaud C., Bach J.F. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996, 26:2989-2998.
44. Falcone M., Yeung B., Tucker L., Rodriguez E., Sarvetnick N. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999, 190:963-972.
45. Esteban L.M., Tsoutsman T., Jordan M.A., Roach D., Poulton L.D., Brooks A., et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol 2003, 171:2873-2878.
46. Jordan M.A., Fletcher J.M., Pellicci D., Baxter A.G. Slamf1, the NKT cell control gene Nkt1. J Immunol 2007, 178:1618-1627.
47. Pilstrom B., Bjork L., Bohme J. Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 1995, 7:806-814.
48. von Herrath M.G., Oldstone M.B. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997, 185:531-539.
49. Bendelac A., Hunziker R.D., Lantz O. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med 1996, 184:1285-1293.
50. Katz J.D., Wang B., Haskins K., Benoist C., Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993, 74:1089-1100.
51. Beaudoin L., Laloux V., Novak J., Lucas B., Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002, 17:725-736.
52. Novak J., Beaudoin L., Griseri T., Lehuen A. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J Immunol 2005, 174:1954-1961.
53. Cain J.A., Smith J.A., Ondr J.K., Wang B., Katz J.D. NKT cells and IFN-gamma establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 2006, 176:1645-1654.
54. Forestier C., Takaki T., Molano A., Im J.S., Baine I., Jerud E.S., et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol 2007, 178:1415-1425.
55. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001, 7:1052-1056.
56. Mi Q.S., Ly D., Zucker P., McGarry M., Delovitch T.L. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Diabetes 2004, 53:1303-1310.
57. Mizuno M., Masumura M., Tomi C., Chiba A., Oki S., Yamamura T., et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004, 23:293-300.
58. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001, 7:1057-1062.
59. Chen Y.G., Choisy-Rossi C.M., Holl T.M., Chapman H.D., Besra G.S., Porcelli S.A., et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005, 174:1196-1204.
60. Burdin N., Brossay L., Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999, 29:2014-2025.
61. Cui J., Watanabe N., Kawano T., Yamashita M., Kamata T., Shimizu C., et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. J Exp Med 1999, 190:783-792.
62. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001, 194:1801-1811.
63. Chen Y.G., Chen J., Osborne M.A., Chapman H.D., Besra G.S., Porcelli S.A., et al. CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol 2006, 177:2939-2947.
64. Ly D., Mi Q.S., Hussain S., Delovitch T.L. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006, 177:3695-3704.
65. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998, 391:177-181.
66. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140.
67. Kis J., Engelmann P., Farkas K., Richman G., Eck S., Lolley J., et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007, 81:654-662.
68. Lee P.T., Putnam A., Benlagha K., Teyton L., Gottlieb P.A., Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002, 110:793-800.
69. Michalek J., Vrabelova Z., Hrotekova Z., Kyr M., Pejchlova M., Kolouskova S., et al. Immune regulatory T cells in siblings of children suffering from type 1 diabetes mellitus. Scand J Immunol 2006, 64:531-535.
70. Montoya C.J., Pollard D., Martinson J., Kumari K., Wasserfall C., Mulder C.B., et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 2007, 122:1-14.
71. Oikawa Y., Shimada A., Yamada S., Motohashi Y., Nakagawa Y., Irie J., et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002, 25:1818-1823.
72. Roman-Gonzalez A., Moreno M.E., Alfaro J.M., Uribe F., Latorre-Sierra G., Rugeles M.T., et al. Frequency and function of circulating invariant NKT cells in autoimmune diabetes mellitus and thyroid diseases in Colombian patients. Hum Immunol 2009, 70:262-268.
73. Tsutsumi Y., Jie X., Ihara K., Nomura A., Kanemitsu S., Takada H., et al. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. Diabet Med 2006, 23:1145-1150.
74. Berzins S.P., Cochrane A.D., Pellicci D.G., Smyth M.J., Godfrey D.I. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 2005, 35:1399-1407.
75. Berzins S.P., Kyparissoudis K., Pellicci D.G., Hammond K.J., Sidobre S., Baxter A., et al. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol Cell Biol 2004, 82:247-252.
76. Kent S.C., Chen Y., Clemmings S.M., Viglietta V., Kenyon N.S., Ricordi C., et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005, 175:4458-4464.
77. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999, 24:511-514.
78. Illes Z., Kondo T., Newcombe J., Oka N., Tabira T., Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000, 164:4375-4381.
79. Araki M., Kondo T., Gumperz J.E., Brenner M.B., Miyake S., Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003, 15:279-288.
80. Mieza M.A., Itoh T., Cui J.Q., Makino Y., Kawano T., Tsuchida K., et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996, 156:4035-4040.
81. Yoshimoto T., Bendelac A., Hu-Li J., Paul W.E. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci USA 1995, 92:11931-11934.
82. Mars L.T., Gautron A.S., Novak J., Beaudoin L., Diana J., Liblau R.S., et al. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 2008, 181:2321-2329.
83. Novak J., Beaudoin L., Park S., Griseri T., Teyton L., Bendelac A., et al. Prevention of type 1 diabetes by invariant NKT cells is independent of peripheral CD1d expression. J Immunol 2007, 178:1332-1340.
84. Furlan R., Bergami A., Cantarella D., Brambilla E., Taniguchi M., Dellabona P., et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol 2003, 33:1830-1838.
85. Jahng A.W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001, 194:1789-1799.
86. Kotzin B.L. Systemic lupus erythematosus. Cell 1996, 85:303-306.
87. Sieling P.A., Porcelli S.A., Duong B.T., Spada F., Bloom B.R., Diamond B., et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000, 165:5338-5344.
88. Zeng D., Dick M., Cheng L., Amano M., Dejbakhsh-Jones S., Huie P., et al. Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines. J Exp Med 1998, 187:525-536.
89. Zeng D., Lee M.K., Tung J., Brendolan A., Strober S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 2000, 164:5000-5004.
90. Zeng D., Liu Y., Sidobre S., Kronenberg M., Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003, 112:1211-1222.
91. Morshed S.R., Mannoor K., Halder R.C., Kawamura H., Bannai M., Sekikawa H., et al. Tissue-specific expansion of NKT and CD5+B cells at the onset of autoimmune disease in (NZBxNZW)F1 mice. Eur J Immunol 2002, 32:2551-2561.
92. Kojo S., Adachi Y., Keino H., Taniguchi M., Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001, 44:1127-1138.
93. van der Vliet H.J., von Blomberg B.M., Nishi N., Reijm M., Voskuyl A.E., van Bodegraven A.A., et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001, 100:144-148.
94. Takeda K., Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993, 177:155-164.
95. Yang J.Q., Saxena V., Xu H., Van Kaer L., Wang C.R., Singh R.R. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003, 171:4439-4446.
96. Wingender G., Kronenberg M. Role of NKT cells in the digestive system. IV. The role of canonical natural killer T cells in mucosal immunity and inflammation. Am J Physiol Gastrointest Liver Physiol 2008, 294:G1-G8.
97. Numata Y., Tazuma S., Ueno Y., Nishioka T., Hyogo H., Chayama K. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 2005, 50:1844-1851.
98. Saubermann L.J., Beck P., De Jong Y.P., Pitman R.S., Ryan M.S., Kim H.S., et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000, 119:119-128.
99. Ueno Y., Tanaka S., Sumii M., Miyake S., Tazuma S., Taniguchi M., et al. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm Bowel Dis 2005, 11:35-41.
100. Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629-638.
101. Ajuebor M.N. Role of NKT cells in the digestive system. I. Invariant NKT cells and liver diseases: is there strength in numbers?. Am J Physiol Gastrointest Liver Physiol 2007, 293:G651-G656.
102. Kaneko Y., Harada M., Kawano T., Yamashita M., Shibata Y., Gejyo F., et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000, 191:105-114.
103. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000, 97:5498-5503.
104. Yanagihara Y., Shiozawa K., Takai M., Kyogoku M., Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999, 118:131-136.
105. Maeda T., Keino H., Asahara H., Taniguchi M., Nishioka K., Sumida T. Decreased TCR AV24AJ18+ double-negative T cells in rheumatoid synovium. Rheumatology (Oxford) 1999, 38:186-188.
106. Chiba A., Kaieda S., Oki S., Yamamura T., Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum 2005, 52:1941-1948.
107. Kim H.Y., Kim H.J., Min H.S., Kim S., Park W.S., Park S.H., et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005, 201:41-47.
108. Chiba A., Oki S., Miyamoto K., Hashimoto H., Yamamura T., Suppression Miyake.S., et al. A sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004, 50:305-313.
109. Coppieters K., Van B.K., Jacques P., Dewint P., Vervloet A., Vander C.B., et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol 2007, 179:2300-2309.
110. Miellot A., Zhu R., Diem S., Boissier M.C., Herbelin A., Bessis N. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 2005, 35:3704-3713.
111. Liu R., La Cava A., Bai X.F., Jee Y., Price M., Campagnolo D.I., et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005, 175:7898-7904.
112. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000, 1:245-251.
113. Lehuen A., Diana J., Zaccone P., Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010, 10:501-513.
114. Novak J., Griseri T., Beaudoin L., Lehuen A. Regulation of type 1 diabetes by NKT cells. Int Rev Immunol 2007, 26:49-72.
115. Griseri T., Beaudoin L., Novak J., Mars L.T., Lepault F., Liblau R., et al. Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells. J Immunol 2005, 175:2091-2101.
116. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002, 195:625-636.
117. Lee P.T., Benlagha K., Teyton L., Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002, 195:637-641.
118. Terashima A., Watarai H., Inoue S., Sekine E., Nakagawa R., Hase K., et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008, 205:2727-2733.
119. Michel M.L., Keller A.C., Paget C., Fujio M., Trottein F., Savage P.B., et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007, 204:995-1001.
120. Laloux V., Beaudoin L., Ronet C., Lehuen A. Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes. J Immunol 2002, 168:3251-3258.
121. Godfrey D.I., Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004, 114:1379-1388.
122. Singh N., Hong S., Scherer D.C., Serizawa I., Burdin N., Kronenberg M., et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999, 163:2373-2377.
123. Diana J., Griseri T., Lagaye S., Beaudoin L., Autrusseau E., Gautron A.S., et al. NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity 2009, 30:289-299.
124. Hayakawa Y., Takeda K., Yagita H., Van Kaer L., Saiki I., Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001, 166:6012-6018.
125. Kim D.H., Chang W.S., Lee Y.S., Lee K.A., Kim Y.K., Kwon B.S., et al. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol 2008, 180:2062-2068.
126. Zaini J., Andarini S., Tahara M., Saijo Y., Ishii N., Kawakami K., et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 2007, 117:3330-3338.
127. Ito K., Karasawa M., Kawano T., Akasaka T., Koseki H., Akutsu Y., et al. Involvement of decidual Valpha14 NKT cells in abortion. Proc Natl Acad Sci USA 2000, 97:740-744.
128. Osman Y., Kawamura T., Naito T., Takeda K., Van Kaer L., Okumura K., et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000, 30:1919-1928.
129. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002, 8:3702-3709.
130. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004, 103:383-389.